2024 Q2 Neurocrine Biosciences earnings estimates revised down by William Blair and Wedbush.

Analysts at William Blair and Wedbush have revised their Q2 2024 earnings estimates for Neurocrine Biosciences (NASDAQ:NBIX), forecasting $1.11/share (down from $1.14) and $1.18/share (down from $1.25), respectively. The consensus estimate for Neurocrine's full-year earnings stands at $4.78/share. Both firms maintain an "Outperform" rating on the company's stock.

May 08, 2024
3 Articles